Go Pro
OTCMKTS:ECTE

Echo Therapeutics (ECTE) Stock Price, News & Analysis

Echo Therapeutics logo
$0.0002 0.00 (0.00%)
As of 09/7/2021

About Echo Therapeutics Stock (OTCMKTS:ECTE)

Key Stats

Today's Range
$0.0002
$0.0002
50-Day Range
N/A
52-Week Range
$0.00
$0.28
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Echo Therapeutics Inc. is a developer of non‐invasive biosensing platforms, with a particular focus on continuous glucose monitoring for diabetes management. The company’s core technology utilizes reverse iontophoresis to extract interstitial fluid through the skin, enabling real‐time glucose measurements without the need for fingerstick blood tests. Over its history, Echo Therapeutics has sought FDA clearance for wearable monitoring devices designed to deliver actionable data to patients and healthcare providers.

Echo Therapeutics’ first commercial product, the GlucoWatch® Biographer, received FDA approval in the early 2000s and represented one of the initial attempts to bring transdermal glucose sensing to market. Although the company faced regulatory and market challenges with its first‐generation device, it continued to refine its sensing platform through research collaborations and strategic partnerships. Echo Therapeutics has historically been based in the United States and has pursued distribution and reimbursement pathways in North America and select international markets.

Building on its proprietary transdermal sensing technology, Echo Therapeutics is exploring applications beyond glucose monitoring, including pharmacokinetic studies and adherence tracking for a variety of therapeutic areas. While information on its current product pipeline and executive team is limited, the company remains focused on advancing minimally invasive diagnostic solutions. Echo Therapeutics trades on the OTC Markets under the symbol ECTE, where it engages with investors regarding its ongoing research and development efforts.

AI Generated. May Contain Errors.

Receive ECTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Echo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ECTE Stock News Headlines

ECTE/BTC - EurocoinToken Bitcoin
What are echo chambers?
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
ECTE/USD Synthetic Historical Data
ECTE Historical Data
See More Headlines

ECTE Stock Analysis - Frequently Asked Questions

Echo Therapeutics' stock was trading at $0.0002 on January 1st, 2026. Since then, ECTE stock has increased by 0.0% and is now trading at $0.0002.

Echo Therapeutics Inc. (OTCMKTS:ECTE) announced its quarterly earnings data on Friday, August, 12th. The medical device company reported ($0.82) earnings per share for the quarter.

Shares of ECTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Echo Therapeutics investors own include DexCom (DXCM), Athersys (ATHX), Blackstone Strategic Credit 2027 Term Fund (BGB), BlackRock Science and Technology Trust (BST).

Company Calendar

Last Earnings
8/12/2016
Today
8/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
OTCMKTS:ECTE
Previous Symbol
NASDAQ:ECTE
CIK
1031927
Employees
19
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (OTCMKTS:ECTE) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners